Table 4 Management of rebleeding in the studied groups
Variables | Sclerotherapy group N: 15 (%) | Cyanoacrylate group N: 11 (%) | |
|---|---|---|---|
Timing | Early rebleeding | 5 (33.33%) | 3 (27.27%) |
Late rebleeding | 10 (66.67%) | 8 (72.73%) | |
Clinical presentation | Hematemesis | 8 (53.33%) | 6 (54.55%) |
Melena | 3 (20%) | 3 (27.27%) | |
Hematemesis and melena | 4 (26.67%) | 2 (18.18%) | |
Causes | Bleeding from the same site and/or post injection esophageal ulcers | 7 (46.67%) | 2 (18.18) |
Bleeding from other sites (OV&GV) | 8 (53.33%) | 9 (81.82) | |
Treatment | Conservative treatment | 6 (40%) | 3 (27.27%) |
Band ligation | 6 (40%) | 6 (54.55%) | |
Cyanoacrylate injection | 3 (20%) | 2 (18.18) | |